Swiss Recommendations for the Follow-Up and Treatment of Pulmonary Long COVID.

Publication Year: 2021

DOI:
10.1159/000517255

PMCID:
PMC8339046

PMID:
34091456

Journal Information

Full Title: Respiration

Abbreviation: Respiration

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pulmonary Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of Interest Statement M.F.C. has received unrestricted grants and/or speaker fees from Boehringer Ingelheim, Roche and Novartis unrelated to this work. C.F.C. has received payments for lectures/speaking, development of educational materials, and travel/accommodation/meeting expenses/ advisory boards from Roche, Novartis, Boehringer, GSK, Astra Zeneca, Sanofi, Vifor, OM Pharma, and Mundipharma. C.v.G. has received honoraria for consulting, advisory role, or lectures from AstraZeneca, Boehringer Ingelheim, GSK, Mundipharma, Novartis, OM Pharma, Pfizer, PneumRx, and Pulmonx Sanofi. The other authors have no conflicts of interest to declare in relation to this work."

Evidence found in paper:

"Funding Sources No funding was received for this work."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025